Dynamic Technology Lab Private Ltd Invests $459,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Dynamic Technology Lab Private Ltd bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,133 shares of the medical equipment provider's stock, valued at approximately $459,000.

Several other large investors also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus in the 4th quarter valued at approximately $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus during the 4th quarter valued at approximately $37,000. UMB Bank n.a. lifted its stake in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its position in Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 in the last three months. 1.50% of the stock is currently owned by insiders.

Lantheus Stock Down 0.5 %

NASDAQ:LNTH traded down $0.54 on Monday, hitting $101.46. The stock had a trading volume of 140,912 shares, compared to its average volume of 953,064. Lantheus Holdings, Inc. has a 52 week low of $59.56 and a 52 week high of $126.89. The business's fifty day moving average is $94.00 and its 200 day moving average is $95.56. The company has a market cap of $6.95 billion, a PE ratio of 16.88 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on LNTH. B. Riley dropped their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. JMP Securities reissued a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial raised their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Lantheus has a consensus rating of "Moderate Buy" and an average target price of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.